Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: KurtVedder who wrote (907)	12/1/1997 1:30:00 AM
From: Grainne	Read Replies (2) \| Respond to of 1359

Kurt, this review is very good news, a bit of cheer at a depressing time. However, I would like to point out that IPIC has gone quite a bit above $33. I am absolutely sure because I bought my last shares at $37 (holding on for dear life)!

To: KurtVedder who wrote (907)	12/1/1997 3:58:00 PM
From: Pancho Villa	Respond to of 1359

Kurt, >>But Frankel says Interneuron has limited liability, ample insurance, $140 millon in cash and several other major drugs now undergoing clinical trials that support his 12-month target price of $22, and 83% rebound form here ($12)".<< IMO, this Mr. Frankel does not know much about the potential liability that IPIC faces. Do your own homework before placing your trust on often mediocre/irresponsible analysts [Probably Mr. Frankel is a very capable analyst but his recommending DELL at this point makes me wonder...] Pancho